Northwest Biotherapeutics Inc Watch

from 8-K 42 pages Northwest Biotherapeutics, Inc. 5.00% Convertible Senior Notes Due 2017 Purchase Agreement

from 8-K 34 pages 4,895,834 Shares Northwest Biotherapeutics, Inc. Common Stock and Warrants to Purchase Up to 2,447,917 Shares of Common Stock Underwriting Agreement

from S-1/A 56 pages Underwriting Agreement Between Northwest Biotherapeutics, Inc. and Aegis Capital Corp., as Representative of the Several Underwriters Northwest Biotherapeutics, Inc. Underwriting Agreement

from S-1/A 57 pages Underwriting Agreement Between Northwest Biotherapeutics, Inc. and Aegis Capital Corp., as Representative of the Several Underwriters Northwest Biotherapeutics, Inc. Underwriting Agreement

from SC 13G/A 1 page Cusip No. 66737p 10 5 Page 7 of 7 Pages Exhibit 1 Joint Filing Agreement Pursuant to Rule 13d-1(k)(1) Under the Securities Exchange Act of 1934, as Amended, the Undersigned Hereby Agree That the Amendment No. 4 to Schedule 13g to Which This Joint Filing Statement Is Being Filed as an Exhibit Shall Be a Joint Statement Filed on Behalf of Each of the Undersigned. Date: May 6, 2004 Northwest Hospital by /S/ C. William Schneider C. William Schneider, President and Chief Executive Officer /S/ C. William Schneider C. William Schneider, Individually

from SC 13D >50 pages Underwriting agreement

from 8-K 1 page Underwriting agreement

from S-1/A ~50 pages Underwriting agreement